Neuramedy Co. Ltd.
Biopharmaceutical company focused on developing disease‑modifying therapies and diagnostics for age‑related neurodegenerative diseases, with an initial emphasis on Parkinson’s disease. Research priorities include antagonizing Toll‑like receptor 2 (TLR2), inhibiting alpha‑synuclein aggregation and propagation, engineering brain‑penetrant biologics, and developing associated diagnostics. The company pursues co‑development and open‑innovation partnerships with academic and industry groups.
Industries
Nr. of Employees
small (1-50)
Neuramedy Co. Ltd.
Patents
Method for measuring cell-to-cell transmission of α-synuclein aggregates using bimolecular fluorescence complementation system and method for screening a substance for preventing or treating neurodegenerative disease using the same
US-9757402-B2
View DetailsComposition and method for treatment of reperfusion injury and tissue damage
US-8734788-B2
View Details
Method for measuring cell-to-cell transmission of α-synuclein aggregates using bimolecular fluorescence complementation system and method for screening a substance for preventing or treating neurodegenerative disease using the same
US-9757402-B2
View DetailsComposition and method for treatment of reperfusion injury and tissue damage
US-8734788-B2
View DetailsProducts
TLR2‑targeting antibody program for Parkinson’s disease
Antibody program designed to antagonize TLR2 to block neuron‑to‑neuron propagation of pathogenic protein and reduce neuroinflammation; advanced through discovery and preclinical stages with programs advancing toward early clinical development.
Blood–brain barrier‑penetrant antibody program
Program to develop antibodies or biologics engineered for enhanced CNS delivery for Parkinson’s and other CNS diseases.
Small‑molecule inhibitors of alpha‑synuclein aggregation
Small‑molecule discovery program aiming to inhibit abnormal protein aggregation implicated in Parkinson’s disease and related synucleinopathies.
Diagnostics for aggregated alpha‑synuclein
Development of diagnostic assays to detect aggregated alpha‑synuclein for CNS disease diagnosis and monitoring.
TLR2‑targeting antibody program for Parkinson’s disease
Antibody program designed to antagonize TLR2 to block neuron‑to‑neuron propagation of pathogenic protein and reduce neuroinflammation; advanced through discovery and preclinical stages with programs advancing toward early clinical development.
Blood–brain barrier‑penetrant antibody program
Program to develop antibodies or biologics engineered for enhanced CNS delivery for Parkinson’s and other CNS diseases.
Small‑molecule inhibitors of alpha‑synuclein aggregation
Small‑molecule discovery program aiming to inhibit abnormal protein aggregation implicated in Parkinson’s disease and related synucleinopathies.
Diagnostics for aggregated alpha‑synuclein
Development of diagnostic assays to detect aggregated alpha‑synuclein for CNS disease diagnosis and monitoring.
Services
Collaborative R&D and co‑development with academic and industrial partners for discovery and optimization of therapeutics and diagnostics.
Collaborative R&D and co‑development with academic and industrial partners for discovery and optimization of therapeutics and diagnostics.
Expertise Areas
- Parkinson's disease therapeutics
- Neuroinflammation and innate immune targets (TLR2)
- Antibody therapeutics for CNS disorders
- Blood–brain barrier delivery engineering
Key Technologies
- Monoclonal antibody development
- TLR2 antagonism strategies
- Alpha‑synuclein aggregation assays
- Blood–brain barrier delivery engineering
News & Updates
Completed Series A financing (reported July 2020).
Selected as a Baby‑Unicorn by the K‑Unicorn 200 project (Ministry of SMEs and Startups).
Received awards including 'Team Korea: Innovative Company 1000' and Minister Award for IP R&D outcomes (Nov 2020).
Seed funding raised and acquisition of rights to a therapeutic antibody program in 2019; joint R&D agreements initiated with partners.
Established research collaborations and MOUs with academic institutions and industry partners for Parkinson’s and Alzheimer’s disease research (2019–2020).
Completed Series A financing (reported July 2020).
Selected as a Baby‑Unicorn by the K‑Unicorn 200 project (Ministry of SMEs and Startups).
Received awards including 'Team Korea: Innovative Company 1000' and Minister Award for IP R&D outcomes (Nov 2020).
Seed funding raised and acquisition of rights to a therapeutic antibody program in 2019; joint R&D agreements initiated with partners.
Established research collaborations and MOUs with academic institutions and industry partners for Parkinson’s and Alzheimer’s disease research (2019–2020).